Korean J Urol.  2006 Jan;47(1):85-90. 10.4111/kju.2006.47.1.85.

Effectiveness of Two Spots Enuretic Voiding Diary for the Treatment of Nocturnal Enuresis

• Oh MM
• Shim KS
• Moon DG

• KMID: 2294221
• DOI: http://doi.org/10.4111/kju.2006.47.1.85

Abstract

PURPOSE: The authors developed a Two Spots Enuretic Voiding Diary (TSEVD) that consisted of the first voiding amount (V1) after awakening and the single voiding amount (V2) for the patient's need to void before sleep. We evaluated the efficacy and usefulness of the TSEVD for the treatment of enuretic children.
MATERIALS AND METHODS
From Apr. 2002 to Feb. 2004, 71 patients with monosymptomatic nocturnal enuresis and 55 patients with polysymptomatic nocturnal enuresis were enrolled in this study. The treatment modality and termination were assigned by the V1, V2 and V3 (age- matched normal bladder capacity) on the TSEVD.
RESULTS
The percent of patients whose V3 exceeded their V2 and their ratios of V1/V2 and V2/V3 were decreased after treatment in both the monsymptomatic and polysymptomatic group. For the monosymptomatic patients, the submission rate, the good response rate and the cure rate were 73.7%, 19.7% and 65.6%, respectively, whereas the submission rate, the good response rate and cure rate for the polysymptomatic patients were 84.4%, 22.9% and 41.7%, respectively. The recurrence rates in both groups were 14.8% and 35.4%, respectively. Both the patients and parents showed good understanding of the TSEVD, the principles of treatment and their role in the treatment. The Student's t-test (paired) was used for the statistical analysis.
CONCLUSIONS
These data suggests that the TSEVD was useful to evaluate the progress of treatment and the treatment goals for each patient suffering with nocturnal enuresis. The treatment end point, based on the TSEVD, was effective in reducing recurrence by determining the treatment effect.

Keyword

Enuresis; Urination; Charts; Treatment effectiveness

MeSH Terms

Child
Enuresis
Humans
Nocturnal Enuresis*
Parents
Recurrence
Treatment Outcome
Urinary Bladder
Urination

Reference

1. Butler RJ, Holland P. The three systems: a conceptual way of understanding nocturnal enuresis. Scand J Urol Nephrol. 2000. 34:270–277.

2. Wille S. Comparison of desmopressin and enuresis alarm for nocturnal enuresis. Arch Dis Child. 1986. 61:30–33.

3. Monda JM, Husmann DA. Primary nocturnal enuresis: a comparison among observation, imipramine, desmopressin acetate and bed-wetting alarm systems. J Urol. 1995. 154:745–748.

4. Hjalmas K, Arnold T, Bower W, Caione P, Chiozza LM, von Gontard A, et al. Nocturnal enuresis: an international evidence-based management strategy. J Urol. 2004. 171:2545–2561.

5. Jung JY, Kim KM. Effects of combined drug therapy in the nocturnal enuretic patients. Korean J Urol. 1998. 39:70–76.

6. Norgaard JP, Pedersen EB, Djurhuus JC. Diurnal anti-diuretic-hormone levels in enuretics. J Urol. 1985. 134:1029–1031.

7. Rushton HG. Nocturnal enuresis: epidemiology, evaluation, and currently available treatment options. J Pediatr. 1989. 114:691–696.

8. Eller DA, Austin PF, Tanguay S, Homsy YL. Daytime functional bladder capacity as a predictor of response to desmopressin in monosymptomatic nocturnal enuresis. Eur Urol. 1998. 33:Suppl 3. 25–29.

9. Hansen MN, Rittig S, Siggaard C, Kamperis K, Hvistendahl G, Schaumburg HL, et al. Intra-individual variability in nighttime urine production and functional bladder capacity estimated by home recordings in patients with nocturnal enuresis. J Urol. 2001. 166:2452–2455.

10. Kawauchi A, Tanaka Y, Naito Y, Yamao Y, Ukimuro O, Yoneda K, et al. Bladder capacity at the time of enuresis. Urology. 2003. 61:1016–1018.

11. Neveus T, Lackgren G, Tuvemo T, Olsson U, Stenberg A. Desmopressin resistant enuresis: pathogenetic and therapeutic considerations. J Urol. 1999. 162:2136–2140.

12. Hjalmas K, Hellstrom AL, Mogren K, Lackgren G, Stenberg A. The overactive bladder in children: a potential future indication for tolterodine. BJU Int. 2001. 87:569–574.

13. Yamanishi T, Yasuda K, Suda S, Ishikawa N. Effect of functional continuous magnetic stimulation on urethral closure in healthy volunteers. Urology. 1999. 54:652–655.

14. Rushton HG, Belman AB, Zaontz MR, Skoog SJ, Sihelnik S. The influence of small functional bladder capacity and other predictors on the response to desmopressin in the management of monosymptomatic nocturnal enuresis. J Urol. 1996. 156:651–655.

15. Neveus T, Lackgren G, Tuvemo T, Hetta J, Hjalmas K, Stenberg A. Enuresis-background and treatment. Scand J Urol Nephrol. 2000. 206:Suppl. 1–44.

16. Rew DA, Rundle JS. Assessment of the safety of regular DDVAP therapy in primary nocturnal enuresis. Br J Urol. 1989. 63:352–353.

17. Lee KH, Suh HJ, Lee T. Combination drug therapy of oxybutynin and desmopressin with primary nocturnal enuresis. Korean J Urol. 2002. 43:753–758.

18. Ye JW, Lee SD. The comparison of therapeutic effect between imipramine and desmopressin on enuretic patients. Korean J Urol. 2001. 42:75–79.

19. Seo YJ, Lee SD, Lee KS. Combination therapy of imipramine and desmopressin in children with monsymptomatic nocturnal enuresis. Korean J Urol. 2001. 42:1322–1327.